PetMed Express Stock (NASDAQ:PETS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.84

52W Range

$1.57 - $4.10

50D Avg

$2.19

200D Avg

$2.59

Market Cap

$39.53M

Avg Vol (3M)

$117.96K

Beta

0.77

Div Yield

-

PETS Company Profile


PetMed Express, Inc., through its various subsidiaries, operates as a prominent pet pharmacy across the United States. The company provides a comprehensive range of both prescribed and over-the-counter animal medications, health-related items, and other essential supplies for canines, felines, and equines. Their non-prescription offerings include products for flea and tick prevention, joint and bone care, vitamins, treats, nutritional supplements, hygiene essentials, and general pet supplies. For prescription needs, they supply heartworm and flea/tick preventatives, alongside medications for conditions such as arthritis, dermatitis, thyroid imbalances, diabetes, pain relief, and cardiovascular issues, often providing generic alternatives. Beyond pharmaceuticals, the company also retails pet food, bedding, crates, stairs, and various other accessories. PetMed Express engages with its clientele through multiple distribution channels: its official website, a dedicated mobile application, a telephone contact center, direct mail campaigns (like brochures and postcards), and television advertisements, frequently promoting its 1-800-PetMeds and PetMeds brands. The company was established in 1996 and is headquartered in Delray Beach, Florida.

Show More

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

287

IPO Date

Apr 26, 1999

Website

PETS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMar 26
Membership$2.30M

Fiscal year ends in Mar 26 | Currency in USD

PETS Financial Summary


Mar 26Mar 25Mar 24
Revenue$179.02M$226.97M$274.10M
Operating Income$-58.67M$-1.53M$-6.96M
Net Income$-57.29M$-6.27M$-7.46M
EBITDA$-47.46M$6.71M$783.00K
Basic EPS$-2.74$-0.30$-0.37
Diluted EPS$-2.74$-0.30$-0.37

Fiscal year ends in Mar 26 | Currency in USD

Latest Earnings Call Transcripts


Q4 26Jun 02, 26 | 12:00 AM
Q3 25Feb 10, 25 | 4:30 PM
Q2 25Nov 06, 24 | 4:30 PM

Peer Comparison


TickerCompany
RNTXRein Therapeutics Inc.
YI111, Inc.
MDCXMedicus Pharma Ltd. Common Stock
FBIOFortress Biotech, Inc.
ICCMIceCure Medical Ltd
BDSXBiodesix, Inc.
TELATELA Bio, Inc.
CTSOCytosorbents Corporation
GNTAGenenta Science S.p.A.
MDAISpectral AI, Inc.